Refine by
Tumor Antigen Articles & Analysis
30 articles found
The firm develops monoclonal antibodies that target tumor-specific antigens through the services. This method shows potential for better patient response rates while simultaneously enabling the detection of tumor progression and resistance mechanisms. ...
Target Identification and Validation: Identifying suitable antigens that are overexpressed in specific cancers is the first step. ...
The monoclonal antibody is designed to bind specifically to cancer cells, ensuring that the toxic drug is delivered directly to the tumor, thereby minimizing damage to healthy cells. This targeted approach enhances the therapeutic index of the drug, resulting in improved efficacy and reduced side effects compared to conventional chemotherapy. ...
The platelet membranes are already bionic coatings that allow nanoparticles to bypass macrophage detection, catch on-target tumour cells and target inflammation sites, studies show recently. Tumor Cell Membrane in Bionic Nanomedicine Tumor cell membrane is produced after normal cells mutate. Recent studies have shown that tumor cells are ideal ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. Alfa Cytology, celebrated for its cutting-edge biotech solutions and extensive tumor research expertise, has recently introduced brain tumor drug development services, designed to empower researchers in understanding the intricacies and unique challenges ...
In the environment of cancer, antigens may be specific to tumor cells and are known as tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs). ...
Compared with traditional cytotoxins, ADCs have the advantages of strong targeting, less toxic side effects, etc. They can accurately target tumor cells, reduce side effects, and improve the therapeutic effect.ADC drugs are mainly composed of monoclonal antibodies, linkers, and small molecule cytotoxins. Their monoclonal antibodies, linkers, linker-cytotoxin molecules, and newly ...
Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. ...
ByTempus
Therefore, it can be well modified on its surface, such as coating with cell membrane, for the design and development of tumor vaccines. CpG is a type of oligodeoxynucleotide that can be used as an immune adjuvant to stimulate the maturation and development of antigen-presenting cells. CpG can be encapsulated with PLGA using the emulsion evaporation method. The ...
Nanobodies are the smallest functional single-domain antibodies known to be able to stably bind to antigens, and have unique structural and functional advantages. The molecular weight of nanobodies is only 12-15 kDa, which retains the antigen binding ability of traditional antibodies. ...
Post transfection or transduction, the ‘armed’ virus proliferates within the cancer cell, causing its lysis, and is then primed to infect other adjacent malignant cells, prompting an exponential eradication of the tumorous growth. The selection of the virus itself is a cornerstone in OV creation. ...
Therefore, the application range of ADCs containing non-cleavable linkers is limited, and they are mainly used for the treatment of hematological cancers or tumors with high antigen expression.Compared with non-cleavable linkers, cleavable linkers use specific conditions to release drugs at target cells. ...
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. ...
Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only expressed in tumor cells but not in normal cells are tumor-specific antigens and the most ideal targets; ...
In this approach, a patient’s T cells are extracted and purified from a blood sample; they are subsequently genetically modified to express a T-cell receptor specific to a tumor antigen unique to the patient’s cancer cells. This receptor is called “chimeric antigen receptor”, or CAR. ...
PSA decreased by 50% in 18% of patients, local radiation reaction occurred in 6% of patients, and transformation to benign cycle tumor cells <5 in 60% of patients. 2. Other ADCs Trophoblast cell surface antigen 2 (TROP2) is a 323 amino acid transmembrane gly- coprotein that is a calcium signal transducer and is responsible for tumor cell ...
Mesothelin or MPF supplementation stimulates lung cancer growth in MSLN knockout mice, which verifies the role of mesothelin in tumor cell adhesion, migration, and metastasis. Role of mesothelin in cancer and signaling Mesothelin is expressed in many solid tumors, most commonly in mesothelioma, epithelial ovarian, and pancreatic cancers, as well as in lung and ...
Advances In CircRNA Research CircRNAs are currently relatively well studied in the field of tumor research. Studies have shown that circRNAs play critical roles in many aspects of multiple malignancies, such as cell cycle and proliferation, apoptosis, vascularization and invasion. Currently, it has been found that circRNAs can act as tumor ...
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell ...
Overexpression of SVN is associated with autoimmune disease, hyperplasia, and tumors and can be used as a biomarker in these diseases. SVN is widely recognized as a tumor-associated antigen (TAA) and has become an important target for cancer diagnosis and treatment. ...